Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $55.2M | $60.9M | $23.9M | $2.24M | $1.32M | $0.00 |
| Revenue growth | — | 10.2% | -60.7% | -90.6% | -40.9% | -100.0% |
| Operating income | $20.6M | -$13.4M | -$28.9M | -$38.1M | -$42.9M | -$49.0M |
| Operating margin | 37.2% | -22.0% | -121.0% | -1700.6% | -3244.9% | — |
| Net income | $20.1M | -$17.1M | -$18.7M | -$42.2M | -$34.1M | $13.3M |
| Net margin | 36.4% | -28.2% | -78.4% | -1884.5% | -2579.0% | — |
| EPS (diluted) | $0.74 | -$0.63 | -$4.31 | -$7.64 | -$3.68 | -$0.79 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $10.0M | $1.99M | -$23.5M | -$25.1M | -$34.3M | -$44.8M |
| Capital expenditures | $12.7M | $10.9M | $2.17M | $197K | $337K | $933K |
| Free cash flow | -$2.73M | -$8.96M | -$25.6M | -$25.3M | -$34.6M | -$45.7M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $12.6M | $33.2M | $15.0M | $56.6M | $8.90M | $10.5M |
| Total assets | $56.5M | $81.1M | $50.9M | $83.9M | $44.2M | $173M |
| Total liabilities | $17.5M | $42.6M | $19.8M | $26.6M | $18.2M | $21.3M |
| Shareholders' equity | $39.0M | $38.5M | $31.1M | $57.3M | $26.0M | $151M |
| Retained earnings | -$12.0M | -$29.1M | -$47.9M | -$90.1M | -$124M | -$111M |
| Shares (wtd avg diluted) | 27.0M | 27.3M | 4.35M | 5.52M | 9.26M | 61.3M |
Every figure is extracted from SAB Biotherapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.